News & Media

Clinical progress, corporate developments, partnerships, and media coverage.

Media2026-08-14

Future PharmaTech's FPT-001 obtains US FDA clinical trial authorization, advancing toward international validation

FPT-001 has obtained an Investigational New Drug (IND) authorization from the US FDA and may begin Phase I/II human trials under the approved protocol — a further international regulatory advance after Australia. FPT-001 targets male erectile dysfunction through an optimization pathway built on a combination of already-approved ingredients, and pairs the AiTOX AI toxicology-prediction platform with the NVIDIA Nemotron LLM to rapidly assess drug safety and metabolic mechanism, accelerating its clinical and international licensing plans.

Source: Economic Daily

Media2026-07-06

Future PharmaTech in Boston — focusing on AI toxicology and drug repurposing

In Boston, Future PharmaTech met with international investors and set out a technology roadmap centered on AI toxicology prediction (AI Toxicology) and drug repurposing, aligned with the global pharmaceutical industry's push to lower R&D costs and raise efficiency. External validation of the models and the quality of clinical data were the focus of attention during the exchange; the company will continue to treat solid clinical validation as the foundation for putting its technology into practice.

Source: GeneOnline Monthly

Media2026-07-04

Future PharmaTech visits Monte Jade New England at MassBio in Boston, deepening Taiwan-US biotech links

On July 1 the Startup Island TAIWAN delegation visited the Monte Jade Science and Technology Association of New England at MassBio headquarters in Boston. Led by DCB Chairman Twu Shiing-Jer, nearly 30 Taiwanese and US biotech professionals gathered for the exchange. Future PharmaTech, one of the five Taiwanese startups on the trip, delivered a pitch presentation on site, raising the international visibility of Taiwan's biomedical startups and deepening Taiwan-US industry links.

Source: OCAC News

Media2026-07-01

Future PharmaTech selected for the NDC/DCB delegation to Boston for East Coast market development

Future PharmaTech was selected for the Taiwanese biomedical startup delegation led by the Development Center for Biotechnology (DCB) under the National Development Council, traveling to Boston for a four-day international investment and business development program. The trip continued DCB's collaboration with MassChallenge with support from Startup Island TAIWAN, and the five selected teams' technologies span AI precision health and cell therapy. Future PharmaTech centers on neurovascular disease drug development, showcasing its capability in designing combination therapies that pair AI-driven drug selection with a nanomedicine platform.

Source: GeneOnline Monthly

Media2026-04-16

Future PharmaTech signs MOU with Yung Shin Pharma

A strategic MOU combining an AI drug-discovery platform with international manufacturing, regulatory, and market-access resources to drive new drugs from clinical development to global commercialization.

Source: Economic Daily

Media2026-04-08

Future PharmaTech's FPT-001 obtains Australian Phase II CTN approval

FPT-001 has cleared the Australian CTN and obtained Phase II approval — a key milestone; FPT-003 is also advancing international licensing in parallel.

Source: Economic Daily

Media2026-03-02

Future PharmaTech files for Phase II trial in Australia for FPT-001

Lead product FPT-001 has submitted its Phase II CTN application to an Australian HREC, formally launching the company's international clinical program.

Source: Economic Daily

Media2025-12-17

Future PharmaTech wins the 22nd National Innovation Award

Recognized for breakthrough pharmaceutical R&D, the company received this year's National Innovation Award (Startup category).

Source: Economic Daily

Corporate2025-10-15

Funding round closed — targeting FDA IND in Q1 2026

A new funding round closed with strong strategic-investor backing. Proceeds will fund preclinical research and trial preparation, targeting FDA IND clearance in Q1 2026.

Source: Economic Daily

Corporate2025-09-09

Notice of full conversion to book-entry shares

Effective Aug 28, 2025, the company's issued common shares are fully converted to book-entry form held under shareholders' names at the central depository.

Corporate2025-06-16

2025 annual shareholders' meeting concludes successfully

Thank you to every shareholder for your participation and support — your feedback drives us forward.

Source: Company notice

Corporate2025-05-29

Dun & Bradstreet enterprise certification delivered

Future PharmaTech earned Dun & Bradstreet (D&B) enterprise certification, raising credibility and international recognition.

Source: D&B certification

Partnership2025-05-14

PBF licenses ED drug to strengthen specialty portfolio

Developed via the 505(b)(2) pathway to accelerate entry into the men's-health and urology specialty market.

Source: Taiwan Healthcare Expo

Media2025-04-06

Future PharmaTech reports progress — two drugs on track

Entering Phase II next year, with potential to compete in the global market.

Source: Economic Daily

R&D2023-11-28

Chao Ming-Wei: detox by day, anti-aging by night — vascular dementia enters clinic next year

Focused on dementia therapy development, bringing new hope to patients.

Source: GeneOnline Monthly